BRD4 and Burkitt lymphoma: ARV0825 exerted rapid, efficient and sustained degradation of BRD4 and lethal activity compared to BET inhibitors in Burkitt lymphoma cells, mantle cell lymphoma cells, post-MPN secondary AML cells, and T-cell ALL cells.717–721 dBET1 was generated by conjugating the BRD4 inhibitor, JQ1, to phthalimide as CRBN.